{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:45:35Z","timestamp":1760057135603,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.ajem.2007.11.031","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T05:36:37Z","timestamp":1222839397000},"page":"932-941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention"],"prefix":"10.1016","volume":"26","author":[{"given":"Marc","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2007.11.031_bib1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0735-1097(96)00053-8","article-title":"Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators","volume":"27","author":"Newby","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2007.11.031_bib2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(03)12712-2","article-title":"Acute myocardial infarction","volume":"361","author":"Boersma","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2007.11.031_bib3","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jacc.2004.07.014","volume":"44","author":"Antman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2007.11.031_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(96)02514-7","article-title":"Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour","volume":"348","author":"Boersma","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2007.11.031_bib5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1056\/NEJM200003233421211","article-title":"Primary angioplasty versus thrombolysis for acute myocardial infarction","volume":"342","author":"Boersma","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/jama.1997.03550230069040","article-title":"Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review","volume":"278","author":"Weaver","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct063503","article-title":"Primary PCI for myocardial infarction with ST-segment elevation","volume":"356","author":"Keeley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0195-668X(02)00618-8","volume":"24","author":"Van de Werf","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajem.2007.11.031_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurheartj\/ehi810","article-title":"Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients","volume":"27","author":"Boersma","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajem.2007.11.031_bib11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa063355","article-title":"Weekend versus weekday admission and mortality from myocardial infarction","volume":"356","author":"Kostis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0002-9149(03)00891-9","article-title":"Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?","volume":"92","author":"Nallamothu","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajem.2007.11.031_bib13","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1001\/jama.283.22.2941","article-title":"Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction","volume":"283","author":"Cannon","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib14","first-page":"e85","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee: heart disease and stroke statistics\u20142006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2007.11.031_bib15","first-page":"e148","volume":"116","author":"WRITING COMMITTEE MEMBERS","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2007.11.031_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non\u2013Q-Wave Coronary Events Study Group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2013Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2007.11.031_bib18","first-page":"1107","article-title":"Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)\u20135 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non\u2013ST-segment elevation acute coronary syndromes","volume":"150","author":"MICHELANGELO OASIS 5 Steering Committee","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajem.2007.11.031_bib19","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non\u2013ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa044259","article-title":"Early invasive versus selectively invasive management for acute coronary syndromes","volume":"353","author":"de Winter","year":"2005","journal-title":"N Engl J Med"},{"issue":"3 suppl","key":"10.1016\/j.ajem.2007.11.031_bib21","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low\u2013molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ajem.2007.11.031_bib22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/jama.295.13.jed60020","article-title":"Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?","volume":"295","author":"Califf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib23","unstructured":"sanofi-aventis U.S. LLC. Lovenox (enoxaparin sodium injection) prescribing information, revised September 2006. Accessed: http:\/\/products.sanofi-aventis.us\/lovenox\/lovenox.html [June 14, 2007]."},{"author":"King","key":"10.1016\/j.ajem.2007.11.031_bib24"},{"key":"10.1016\/j.ajem.2007.11.031_bib25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"author":"Morrow","key":"10.1016\/j.ajem.2007.11.031_bib26"},{"key":"10.1016\/j.ajem.2007.11.031_bib27","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jacc.2007.01.093","article-title":"Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial","volume":"49","author":"Gibson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2007.11.031_bib28","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1161\/CIRCULATIONAHA.105.573550","article-title":"Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials","volume":"112","author":"Eikelboom","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2007.11.031_bib29","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/eurheartj\/ehl088","article-title":"A comparison of pharmacologic therapy with\/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study","volume":"27","author":"Armstrong","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajem.2007.11.031_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"issue":"1 suppl","key":"10.1016\/j.ajem.2007.11.031_bib31","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1378\/chest.119.1_suppl.95S","article-title":"New anticoagulant drugs","volume":"119","author":"Weitz","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ajem.2007.11.031_bib32","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusef","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib33","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non\u2013ST-segment elevation acute coronary syndromes","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib34","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.106.620815","volume":"114","author":"Alexander","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2007.11.031_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11239-006-5708-0","article-title":"Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb\/IIIa inhibitors: results from the CRUSADE initiative","volume":"21","author":"Singh","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ajem.2007.11.031_bib36","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjcard.2006.01.047","article-title":"ACOS Registry participants: clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice","volume":"98","author":"Zeymer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajem.2007.11.031_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","article-title":"Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non\u2013ST-Segment elevation acute coronary syndromes: a systematic overview","volume":"292","author":"Petersen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2007.11.031_bib39","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low\u2013molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"author":"Montalescot","key":"10.1016\/j.ajem.2007.11.031_bib40"},{"key":"10.1016\/j.ajem.2007.11.031_bib41","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1056\/NEJMc061206","article-title":"Fondaparinux versus enoxaparin in acute coronary syndromes","volume":"354","author":"Majure","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib42","first-page":"2830","article-title":"Fondaparinux versus enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2007.11.031_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.105.170815","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2007.11.031_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2005.09.007","article-title":"Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial","volume":"152","author":"Rajagopal","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajem.2007.11.031_bib45","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675707007966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675707007966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:10:17Z","timestamp":1760022617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675707007966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0735675707007966"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2007.11.031","relation":{},"ISSN":["0735-6757"],"issn-type":[{"type":"print","value":"0735-6757"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2007.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}